---
title: Improve balance using telerehabilitation games
nct_id: NCT05773885
phase: NA
status: RECRUITING
sponsor: IRCCS San Raffaele Roma
study_type: INTERVENTIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT05773885"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT05773885"
last_fetched: "2026-05-10T14:05:23.645Z"
source: "Parkinson's Pathways (curated)"
---
# Improve balance using telerehabilitation games

**Goal (in five words):** Improve balance using telerehabilitation games

**Official Title:** Home Telerehabilitation Based on Serious Games for Continuity of Care in People With Parkinson's Disease

**Trial ID:** [NCT05773885](https://clinicaltrials.gov/study/NCT05773885)

## Key Facts

- **Phase:** NA
- **Status:** RECRUITING
- **Study Type:** INTERVENTIONAL
- **Sponsor:** IRCCS San Raffaele Roma
- **Target Enrollment:** 40 participants
- **Start Date:** 2022-09-01
- **Completion Date:** 2025-03-30
- **Conditions:** Parkinson's Disease
- **Interventions:** VRRS Tablet (Khymeia s.r.l., Noventa Padovana, Italy), Conventional rehabilitation
- **Intervention Types:** DEVICE, OTHER

## Summary For Families

The goal is to keep people with mid-stage Parkinson's connected to regular rehab at home so they can maintain mobility, balance, and daily function between clinic visits. The approach uses a VRRS tablet with serious games, which deliver guided, gamified physical exercises that adjust difficulty, give immediate feedback, track performance, and let therapists supervise remotely; it is being compared to conventional in-person rehabilitation. They are enrolling people 30 to 80 years old with Parkinson's by MDS criteria, Hoehn and Yahr stage 2 to 3 ON, minimal dyskinesias (MDS-UPDRS items 4.1 and 4.2 ≤ 2), MoCA ≥ 18, stable medications, home internet access, and a caregiver available for sessions.

## Eligibility

- **Minimum age:** 30 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* age between 30 and 80 years;
* diagnosis of Parkinson's Disease according to the "Movement Disorders Society's diagnostic criteria";
* Hoehn \& Yahr (H\&Y) score between 2 and 3 (ON-state);
* absence of dyskinesias assessed by the MDS-UPDRS with a score to items 4.1 and 4.2 ≤ 2;
* absence of cognitive impairment measured by the MoCA total score ≥ 18;
* stabilized drug treatment;
* have access to the Internet for TR;
* have a caregiver available during rehabilitation sessions in TR;
* have sufficient cognitive and linguistic level to understand and comply with study procedures;
* sign informed consent.

Exclusion Criteria:

* having any cognitive problems or low compliance that prevent using the TR system;
* other neurological pathologies, psychiatric complications or personality disorders;
* musculoskeletal diseases that impair movement;
* presence of dyskinesias assessed by the MDS-UPDRS with a score to items 4.1 and 4.2 \> 2;
* presence of cognitive impairment measured by the MoCA total score \< 18;
* severe cognitive or linguistic deficits (inability to understand and comply with study procedures);
* presence of blurred or low vision problems;
* hearing and speech impairment affecting participation in the system;
* absence of signature of the informed consent.
```

## Locations (2)

- San Raffaele Cassino, Cassino, Frosinone, Italy _(41.4858, 13.8284)_
  - Maria Francesca De Pandis, MD. — (CONTACT) — maria.depandis@sanraffaele.it
  - Maria Gaglione, Dr. — (SUB_INVESTIGATOR)
  - Lorenza Leonardi, Dr. — (SUB_INVESTIGATOR)
  - Francesco Barbato, MD — (SUB_INVESTIGATOR)
  - Catia Apisa, Dr. — (SUB_INVESTIGATOR)
- IRCCS San Raffaele Roma, Rome, Italy, Italy _(41.8919, 12.5113)_
  - Dr. Lucia Gatta, PhD — (CONTACT) — lucia.gatta@sanraffaele.it
  - Prof. Fabrizio Stocchi, MD, PhD — (SUB_INVESTIGATOR)
  - Dr. Laura Vacca, MD — (SUB_INVESTIGATOR)

## Central Contacts

- Dr. Sanaz Pournajaf, DPT — (CONTACT) — +39 0652252405 — sanaz.pournajaf@sanraffaele.it
- Dr. Raimondo Torcisi, PT — (CONTACT) — raimondo.torcisi@sanraffaele.it

---

*Canonical: https://parkinsonspathways.com/trial/NCT05773885*  
*HTML version: https://parkinsonspathways.com/trial/NCT05773885*  
*Source data: https://clinicaltrials.gov/study/NCT05773885*